SYDNEY, AUSTRALIA: PharmX Technologies Limited (ASX: PHX) has officially named Tom Culver as its CEO effective from 20 November 2023, as announced by the company’s Board. Culver brings to PharmX a wealth of experience gained from leading innovative technology companies, where he successfully drove sales and implemented growth strategies over his 20-year career.
His diverse background spans founding and owning businesses, as well as holding senior leadership roles in both public and private sector organizations, catering to both B2B and consumer-focused enterprises.
The appointment of Tom Culver aligns with PharmX’s strategic direction, particularly as the company positions itself for growth following substantial recent investments in its EDI gateway and Marketplace capabilities. Culver’s extensive expertise in technology, growth, and leadership is deemed crucial as PharmX shifts its focus towards revenue expansion, delivering exceptional customer engagement, and elevating its presence among enterprise providers and pharmacists in Australia and New Zealand.
Expressing his enthusiasm, Tom Culver stated, “I am excited to have the opportunity to lead PharmX, a Company with an impressive legacy and a fantastic community, as we embark on the next chapter of growth. The prospect of leading a company focused on solving real customer problems for an industry that is evolving with the changing regulatory, consumer, and technology trends is an incredibly exciting challenge.”
In light of this appointment, Nick England, the previous CEO, will transition back to his role as non-executive Chairman. Commenting on the new leadership, England stated, “The Board is delighted to have appointed a candidate of Tom’s calibre and skillset to drive growth and capitalize on the repositioning of the business that has taken place over the last two years.”